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Abstract
Background: Bronchopulmonary dysplasia (BPD) is a major cause of mortality and long-term respiratory and
neurological morbidity in very preterm infants. While survival rates of very preterm infants have increased over
the past two decades there has been no decrease in the rate of BPD in surviving infants. Evidence from animal
and human studies has suggested potential benefits of docosahexaenoic acid (DHA), an n-3 long chain polyunsaturated
fatty acid, in the prevention of chronic lung disease. This randomised controlled trial aims to determine the
effectiveness of supplementary DHA in reducing the rate of BPD in infants less than 29 weeks’ gestation.
Methods/design: This is a multicentre, parallel group, randomised, blinded and controlled trial. Infants born
less than 29 weeks’ gestation, within 3 days of first enteral feed and with parent informed consent are eligible
to participate. Infants will be randomised to receive an enteral emulsion containing DHA or a control emulsion
without DHA. The DHA emulsion will provide 60 mg/kg/day of DHA. The study emulsions will continue to
36 weeks’ postmenstrual age (PMA). The primary outcome is BPD as assessed by the requirement for supplemental
oxygen and/or assisted ventilation at 36 weeks’ PMA. Secondary outcomes include the composite of death or BPD;
duration of respiratory support and hospitalisation, major neonatal morbidities. The target sample size is 1244
infants (622 per group), which will provide 90 % power to detect a clinically meaningful absolute reduction of
10 % in the incidence of BPD between the DHA and control emulsion (two tailed α =0.05).
Discussion: DHA supplementation has the potential to reduce respiratory morbidity in very preterm infants. This
multicentre trial will provide evidence on whether an enteral DHA supplement reduces BPD in very preterm infants.
Trial registration: Australia and New Zealand Clinical Trial Registry: ACTRN12612000503820. Registered 09 May 2012.
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Bronchopulmonary dysplasia (BPD) is a serious lung dis-
ease occurring in infants born prematurely, with those
born at less than 29 weeks’ gestation most at risk. BPD
is characterised by the need for supplemental oxygen
and/or assisted ventilation at 36 weeks’ postmenstrual
age (PMA) [1].
Children with BPD are adversely affected through
childhood, imposing an extra burden on families, health
and education services. In adjusted comparisons involv-
ing preterm peers, children who develop BPD have
poorer cardio-respiratory outcomes, including reduced
airflow, pulmonary hypertension, limited exercise toler-
ance in later childhood [2, 3], and a greater rate of re-
hospitalisation (40–60 vs. 25 %) with longer hospital
stays and multiple re-admissions [4]. Such babies also
have poorer neurological outcomes than preterm infants
without BPD including double the rate of cognitive and
motor delay at pre-school age, up to a 1/3 standard devi-
ation lower intelligence quotient at school age, more
school-based problems including difficulty with reading,
mathematics and spelling, a 50 % greater likelihood of
needing educational assistance at school, a greater need
for speech therapy (50 vs. 20 %) and an increased inci-
dence of cerebral palsy (15 vs. 3 %) [4]. Reducing BPD
would result in savings not only for the health service,
but also for families and education services.
In BPD, the lung develops abnormally, with decreased
vascular and alveolar development resulting in larger but
fewer alveoli. This abnormal lung development results
from a process of chronic inflammation [5]. The risk of
BPD is inversely related to gestational age. Risk factors
that contribute to a pulmonary inflammatory response
include perinatal infection, surfactant deficiency, baro-
trauma, volutrauma and oxygen toxicity [5].
Docosahexaenoic acid (DHA) supplementation and
respiratory function in infants
In infants born at term, several small, randomised con-
trolled trials involving toddlers and children, have shown
improved respiratory outcomes in those who consumed
formula supplemented with DHA [6–9]. However, there
have been no trials specifically designed to determine
the effect of DHA supplementation on BPD in preterm
infants.
Preterm infants are well recognised as being at risk of
DHA insufficiency and have lower blood DHA levels at
birth compared with newborn term infants. Early trials
involving DHA supplementation of preterm showed im-
provement in visual function and on this basis all pre-
term infant formula is now supplemented with DHA at
an amount equivalent to that naturally occurring in the
breast milk of women consuming a Western diet (0.2–
0.3 % of total fatty acids). However, no clinical benefit
on BPD was shown in these early trials [10]. Support for
a role of DHA in the development of BPD comes from
recent observational data showing that a decreased
blood DHA level in infants born less than 30 weeks’ ges-
tation was associated with an increased risk of BPD (OR
2.5 95 % CI 1.3 to 5.0) [11].
The best evidence, however, comes from our DINO
trial [12]. In the DINO trial the effect on neurodevelop-
ment of breast milk or preterm formula with a DHA
concentration of ≈ 1 % of total fatty acids (the estimated
in utero accretion rate) was compared with the current
standard breast milk or preterm formula DHA concen-
tration (≈0.30 % of total fatty acids) in 657 infants born
less than 33 weeks’ gestation [12]. Although the study
was not designed to test BPD, an exploratory analysis in
the sub-group of infants born less than 29 weeks’ gesta-
tional age (n = 225), there was a near significant reduc-
tion in infants requiring supplemental oxygen at
36 weeks’ PMA (high-DHA 38.6 % vs. standard DHA
51.4 %; RR 0.75, 95 % CI 0.55 to 1.03, P = 0.08, unpub-
lished data).
How might DHA improve outcomes?
The parenteral lipids administered to preterm infants
as well as most breast milks and infant formulas are
rich in the n-6 fatty acid linoleic acid (LA). This fatty
acid acts as a precursor for arachidonic acid (AA) that
gives rise to pro-inflammatory eicosanoids and cyto-
kines and also acts as an inhibitor of DHA accumula-
tion in cells. On the other hand, DHA, an n-3 long-
chain polyunsaturated fatty acid (LCPUFA), together
with eicosapentaenoic acid (EPA) can be incorporated
into membrane phospholipids of immune cells, where
they serve as precursors for the synthesis of eicosanoids
and docosanoids. These in turn can alter cytokine pro-
duction and modulate immune cell function and sup-
press inflammatory responses [13–15]. The presence of
n-3 LCPUFA lowers the production of inflammatory ei-
cosanoids and cytokines through competition with AA,
both as a substrate for cyclooxygenase/lipoxygenase ac-
tivity, and by inhibiting the conversion of LA to AA
[15]. When n-3 LCPUFA are the substrates, less inflam-
matory mediators are produced. Thus, incorporation of
n-3 LCPUFA into lipid membranes and elsewhere may
modulate inflammatory activity.
The balance of n-3 LCPUFA and AA is important.
For example, an in vitro study using a human lung car-
cinoma cell line showed that pro-inflammatory cyto-
kine release was reduced with the supply of a high
proportion of DHA and was increased with a high pro-
portion of AA [16]. This concept is supported in two
preterm infant trials. In our DINO trial [12, 17] the
DHA: AA ratio was 2:1, thus favouring the production
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of anti-inflammatory mediators, and beneficial effects
on respiratory function were found in very preterm in-
fants. In the only other trial which used a DHA dose
reflective of the estimated in utero accretion rate, DHA
was supplemented together with AA in a 1:1 ratio, and
a trend towards increased duration of supplemental
oxygen and a need for assisted ventilation in the sup-
plemented group were reported [18].
The beneficial effect of DHA on lung function is sup-
ported by animal studies. For example, in murine
models of hyperoxia-induced lung injury, DHA supple-
mentation reduced inflammatory responses and im-
proved lung growth [19–21]. Separate studies have also
demonstrated that exposure to high DHA increased the
production of dipalmatoylphosphtidylcholine, the major
surfactant lipid in the fetal and neonatal lung [22, 23].
Overall, there are clearly biologically plausible mecha-
nisms by which n-3 LCPUFA, predominantly as DHA,
can contribute to reducing the incidence of BPD.
Method of enteral supplementation
While supplementing lactating women with DHA in-
creases the DHA content of their breast milk, maternal
compliance and biological variation, along with the ne-
cessary delays in establishing full enteral feeds in this
population, means that there is an inconsistent delivery
of DHA to the infant. These limitations can be over-
come by direct DHA supplementation to the infant,
which eliminates the need for maternal compliance or
for the infant to be on full enteral feeds in order to re-
ceive the target dose.
We have determined that direct enteral DHA supple-
mentation is safe and effective in preterm infants [24].
The oral supplement can be commenced within the first
days of enteral feeding and is well tolerated, with no ef-
fect on the number of days feeds were interrupted or the
time taken to reach full enteral feeds. The dietary DHA
level was directly related to blood DHA levels.
Need for a trial
BPD is a leading cause of mortality and long-term mor-
bidity in infants born less than 29 weeks’ gestational age.
As the survival rate of infants less than 29 weeks’ gesta-
tional age continues to increase, with no reduction in
the incidence of BPD, the clinical and health care burden
grows. A randomised controlled trial of the use of DHA
as a simple, safe and cost-effective strategy for the re-
duction of BPD in preterm infants is needed.
Objectives
The primary objective of this study is to determine the
effect of DHA supplementation on the incidence of
BPD in infants born less than 29 weeks’ gestational age,
assessed by the requirement for supplemental oxygen
and/or assisted ventilation at 36 weeks’ PMA, com-
pared with control.
Key secondary objectives of this study include:
 The composite endpoint of death before 36 weeks’
PMA or BPD
 Respiratory support requirements, including the
duration of respiratory support, the use of caffeine
and the use of postnatal steroids and diuretics
for lung disease.
 Severity of BPD
 Feeding tolerance
 Growth
 Length of hospital stay
Other secondary objectives include retinopathy of pre-
maturity, intra-ventricular haemorrhage, cystic periven-
tricular leukomalacia or porencephaly, sepsis, necrotising
enterocolitis and death during first hospitalisation.
Methods
Trial design
The N3RO trial is designed as a randomised, controlled,
clinician, researcher and participant/family blinded, multi-
centre trial with two parallel groups and a primary out-
come of requirement for supplemental oxygen and/or
assisted ventilation at 36 weeks’ PMA.
Participating centres
The sponsoring institution and Trial Coordinating Centre
is the Women’s and Children’s Health Research Institute,
Adelaide, South Australia. The trial is being conducted in
the following 13 perinatal centres:
Australia: Flinders Medical Centre, Adelaide; Women’s
and Children’s Hospital, Adelaide; Royal Women’s
Hospital, Melbourne; John Hunter Hospital, Newcastle;
Monash Medical Centre, Melbourne; King Edward
Memorial Hospital, Perth; Mercy Hospital for Women,
Melbourne; Liverpool Hospital, Sydney; Royal Hospital
for Women, Sydney; Mater Mothers’ Hospital,
Brisbane.
New Zealand: Wellington Hospital, Wellington;
Waikato Hospital, Hamilton.
Singapore: KK Women’s and Children’s Hospital.
Study population
Participants are preterm infants born at less than 29 weeks’
gestation.
Inclusion criteria
Each infant must meet all of the following criteria to be
enrolled in this study:
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1. Born at less than 29 weeks’ gestational age.
2. Within 3 days of commencing enteral feeds.
3. Has a legally acceptable representative
(parent(s)/guardian) capable of understanding
the informed consent document and providing
consent on their (the infant’s) behalf.
Exclusion criteria
1. Infants who have a major congenital or
chromosomal abnormality.
2. Women providing breast milk who are taking
supplements providing > 250 mg DHA per day
and do not wish to stop taking supplements.
3. Infants participating in another fatty acid study.
4. Infants receiving intravenous lipid emulsions
containing fish oil when used as early lipid
parenteral nutrition support (e.g. Omegaven,
SMOFlipid, Lipoplus).
Study treatments
Participating infants will be randomised to the DHA
emulsion or control emulsion receiving an oral supple-
ment providing either 60 mg/kg/day of DHA or no DHA
respectively. The study emulsions are identical in viscosity,
colour, packaging and labelling and are iso-caloric.
DHA emulsion
The DHA emulsion will be administered to provide
60 mg/kg/day of DHA. The microencapsulated aqueous
emulsion of a DHA-rich triglyceride delivers an enteral
DHA dose of 60 mg in 0.5mL. The DHA emulsion will
be administered in three divided doses of 0.17 mL of
emulsion/kg/dose for a total daily volume of 0.5 mL/kg/
day.
Control emulsion
The control emulsion contains soy oil. The same volume
of control emulsion will be given as for the intervention
emulsion; i.e. a total daily volume of 0.5 mL/kg/day
given in three divided doses of 0.17 mL/kg/dose.
Administration
Both the DHA and control emulsions will be administered
enterally through the naso/oro-gastric tube immediately
preceding a scheduled feed. If the infant’s feeds are
stopped the emulsion is also withheld, with administration
recommenced as soon as feeds have been restarted.
The study emulsions are ready to administer, requiring
no preparation. Storage and dispensing of the study
emulsion will be done by the site pharmacists or nom-
inee. The emulsion is to be administered by registered
or enrolled nurses according to local practices. The
study emulsion will be kept refrigerated and has a shelf
life of 9 months. Once opened, the study emulsion will
be discarded after 28 days.
The study emulsion will begin as soon as possible after
consent and randomisation and will continue until
36 weeks’ PMA or discharge home, whichever occurs
first. The local investigator at each centre (or nominee)
will prescribe the study emulsion on the infant’s medica-
tion chart. The dose calculation will be checked weekly
against the current weight of the infant; birthweight is
used until birthweight is regained, then current weight
used. The investigator (or nominee) will be notified if
re-adjustment of the order based on weight is needed.
Manufacture of study emulsion
The study emulsions are manufactured in a licensed fa-
cility (licensed according to the Code of Good Manu-
facturing Practice (GMP) and have been donated to the
trial by Clover Corporation Limited (Clover Corp),
Australia. The emulsions are packaged and labelled in
accordance with GMP including individual product ID,
batch number, retest date and include the statement
“for clinical trial use only”. The study emulsion is sup-
plied as a box of four, 30 mL plastic screw top bottles
containing 20 mL of emulsion in each bottle. An inven-
tory is kept of the emulsion supplies at all sites. The
emulsion will be labelled N3RO study emulsion and
stored refrigerated.
Monitoring adherence
The research nurse in each centre will monitor medica-
tion charts and record number of doses of emulsion
given per day, to ensure compliance.
Concomitant care
Apart from the administration of the study emulsion all
clinical management of infants enrolled in the N3RO
trial will be undertaken under the direction of neonatol-
ogists according to local protocols. The use of intraven-
ous lipid emulsions containing fish oil when used as a
rescue therapy for Parenteral Nutrition Associated Liver
Disease will be at the discretion of the attending neonat-
ologist and local protocols.
Outcome measures
Primary outcome measure
The primary outcome, the incidence of BPD, will be de-
fined on a physiologic basis that combines oxygen and
ventilation support with an assessment of oxygen satur-
ation [25]. The diagnosis of BPD will be determined at
36 completed weeks’ PMA (36 weeks and 0 days to
36 weeks and 6 days inclusive) or day of discharge home,
whichever occurs first.
Infants receiving endotracheal mechanical ventilation,
continuous positive airway pressure [25] or air or
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supplemental oxygen delivered by a high flow device at ≥
2 litres per minute [26] will be classified as having BPD
without additional testing. For infants on nasal cannula
with a flow < 2 litres per minute the “effective” oxygen
concentration will be determined using the Benaron-
Benitz formula [27]. Infants receiving supplemental oxy-
gen concentration ≥ 30 % with oxygen saturations be-
tween 90 and 96 % (inclusive) will be classified as having
BPD without additional testing [25]. Infants in supplemen-
tal oxygen < 30 % at rest with oxygen saturations ≥ 90 %
or oxygen ≥ 30 % with saturations > 96 % [25] or sub-
nasal air at < 2 litres per minute will undergo a timed
(20 min) stepwise (every 5 min) reduction to room air. In-
fants failing the reduction phase (oxygen saturation 80%
to 89% for 5 consecutive minutes, or < 80% for 15 sec-
onds, or apnoea and/or bradycardia with saturation <
90%) or room air phase (oxygen saturation < 90% over a
30 minute period) will be classified as having BPD [25].
Infants in room air at the time of the assessment will have
a 15 min oximetry assessment. Infants failing this (oxygen
saturation < 90 %) will be classified as having BPD.
Secondary outcome measures
A range of standard clinical outcomes for preterm in-
fants < 29 weeks’ gestation are being collected including:
 Death before 36 weeks’ PMA or BPD;
 Respiratory support requirements including the
duration of respiratory support from birth to
36 weeks’ PMA and from birth to 40 weeks’ PMA
or discharge home whichever occurred first;
discontinuation of endotracheal ventilation,
non-invasive positive pressure support and low
flow or supplemental oxygen to 40 weeks’ PMA
or discharge home, whichever occurred first; the
use of caffeine and total days caffeine from birth
to 40 weeks’ PMA or discharge home, whichever
occurred first; the use of postnatal steroids for lung
disease ; the use of diuretics for lung disease and
total days of diuretic use from birth to 40 weeks’
PMA or discharge home, whichever occurred first;
the severity of BPD classified as mild/moderate/
severe according to consensus definitions [1]; BPD
classified according to supplemental oxygen or any
respiratory support at 36 weeks’ PMA or discharge
home whichever occurs first, according to clinical
management at that time.
 Feeding tolerance assessed by number of days to
reach enteral intake ≥ 120 mLs/kg/d and number of
days on which one or more feeds were withheld up to
the primary outcome.
 Growth – weight, length and head circumference
z scores at 36 weeks’ PMA and 40 weeks’ PMA or
discharge home, whichever occurred first.
 Deaths before 36 weeks' PMA and during 1st
hospitalisation.
 Length of hospital stay to first discharge home.
 Retinopathy of prematurity (stage ≥3), and that
requiring treatment.
 Intra-ventricular haemorrhage – any grade and
grade III or IV.
 Cerebral cyst formation – including periventricular
leukomalacia and porencephalic cysts.
 Sepsis and necrotising enterocolitis.
Clinical data will be collected in accordance with the
definitions of the Australia and New Zealand Neonatal
Network [28].
Participant timeline
Infants will receive treatment from enrolment until
36 weeks’ PMA and follow-up will occur until 40 weeks’
PMA or to discharge home, whichever occurs first. At
baseline, a 30 μL infant blood sample for fatty acid ana-
lysis will be taken, weight, length and head circumfer-
ence will be measured and baseline clinical and
demographic data collected. Weekly compliance data
and monthly weight, length and head circumference
measurements will be collected. At 36 weeks’ PMA the
primary outcome will be assessed, infant weight, length
and head circumference will be measured, an infant
blood sample (30 μL) will be collected for fatty acid ana-
lysis and, if available, a 30 μL breast milk sample (also
for fatty acid analysis) will be collected. Secondary out-
come data will be collected up to 40 weeks’ PMA or dis-
charge home, whichever occurs first. The date of first
discharge home will also be recorded.
Sample size estimation
The rate of BPD in infants born less than 29 weeks’ ges-
tation in the DINO trial was 51.4 %. To detect a 10 %
absolute reduction (19 % relative reduction) in the inci-
dence of BPD at 36 weeks’ PMA from 51.4 to 41.4 %
(with 90 % power, two tailed α =0.05) between the DHA
emulsion and control emulsion, a sample size of 1244 is
required (622 per group). This sample size takes into ac-
count the clustering (non-independence) of multiple
births (variance inflation factor 11 %) and deaths (4 % as
estimated from the DINO trial). The variance inflation
factor for multiple births was based on 26 % of infants
born less than 29 weeks’ gestational age being from mul-
tiple births, an intracluster correlation coefficient for
BPD of 0.52 and an average cluster size of 2.07 for these
infants (as observed in the DINO trial in which mothers
were randomised). While the variance inflation factor
may be reduced by randomising infants rather than
mothers, the calculated sample size ensures sufficient
power even in the unlikely event that all infants from
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multiple births are randomised to the same treatment
arm as their siblings.
Recruitment
The research nurse will assess infants for eligibility. The
parent(s)/guardians of eligible infants will be approached
to enter the trial by the local investigator of each centre
(or nominee), ideally within 24 to 48 h of birth. If
women are in hospital threatening very preterm delivery
then, where possible, information about the study will be
provided antenatally.
The information sheet will describe the purpose of the
study, the procedures to be followed, and the risks and
benefits of participation. The investigator, or nominee,
will conduct the informed consent discussion and will
check that information provided is understood and an-
swer any questions about the study. Consent will be vol-
untary and free from coercion. Parents willing for their
infant to participate will sign a written consent form. A
copy of the consent form will be given to the parents
and also documented in the infant’s medical record and
study Case Report Form. Once consent and the eligibil-
ity of the infant is confirmed, the infant will be rando-
mised and the study emulsion assigned.
A record of all infants screened, enrolled and not
enrolled will be maintained. Parent(s)/guardians may
withdraw their child from the study for any reason at
any time. The reason for withdrawal will be recorded.
Whenever possible, parent(s)/guardians of infants who
are withdrawn from the study will be asked permission
to collect follow-up data relevant to the study.
Randomisation procedures
A computer generated randomisation schedule using
balanced variable block design has been generated by an
independent statistician who is not involved with trial
participants or data analysis. Stratification occurred for
sex, study centre and gestational age less than 27 com-
pleted weeks’ and 27 to 28 completed weeks’. Infants
from multiple births will be randomised individually.
The schedule is kept by the independent statistician and
the treatment allocation of each randomisation code can
be provided to the investigator in case of emergency.
Upon consent, infants are randomised using a custo-
mised, purpose built web-based randomisation service.
A unique study ID and a study pack with a unique
product ID are assigned. The study ID identifies the
randomised infant. The product ID identifies a study
box containing four bottles of study emulsion, all la-
belled with the same product ID. Each box of study
emulsion will contain either intervention or control emul-
sion, pre-packed according to the randomisation schedule.
Blinding
Participants and their family, care providers, data collec-
tors, outcome assessors, research personnel and data an-
alysts will all be blinded to randomisation group. The
intervention and control emulsions are identical in vis-
cosity, colour, packaging and labelling and uniquely
identified only by a product ID.
Emergency unblinding
The randomisation code for an individual participant may
only be unblinded in an emergency situation, where the
investigator decides a participant cannot be adequately
treated without knowing their treatment allocation. The
Principal Investigator must be contacted and all attempts
to avoid breaking the code (i.e. withdrawal of treatment)
should be made. To break the randomisation code the
Investigator must contact the randomisation facility/
personnel. The time, date, participant number and reason
for unblinding must be documented and events leading to
the emergency breaking will be recorded.
Data collection and management
Data are collected by trained research nurses/coordina-
tors at each participating centre onto carbon copy paper
Case Report Forms. Data entry and management are co-
ordinated from the Data Management and Analysis
Centre (DMAC) at The University of Adelaide under the
direction of the study statistician (TRS). There are regu-
lar blinded reviews of data quality and data checks using
established protocols. Data discrepancy inquiries and re-
sponses are managed through a secure web-based man-
agement information system.
The Case Report Forms are stored in a locked office at
each study site. Only research staff directly involved in the
study will have access to the information. Electronic forms
of data are stored on secure servers at DMAC. Data are
released only to persons authorised to receive those data.
Original/copies of study documents will be retained at
each study site or in archives. No paper records are
retained by DMAC at study closeout, all are returned to
the coordinating centre, the Women’s and Children’s
Health Research Institute. Documents will be retained
for at least 30 years after study completion in line with
the data retention schedules for research involving mi-
nors. At the completion of this time documentation will
be destroyed using confidential document disposal. The
study electronic data will be stored indefinitely on
DMACs secure servers with access only granted to
authorised study personnel.
Statistical methods
All participants will be analysed according to the group to
which they were randomised (intention-to-treat principle).
The incidence of BPD will be compared between groups
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using a log binomial regression model with a general-
ised estimating equation used to account for depend-
ence due to multiple births. The difference between the
groups will be expressed as a relative risk with a 95 %
confidence interval. Adjustment will be made for ran-
domisation strata (study centre, sex and gestational age
less than 27 completed weeks and 27 to less than 29
completed weeks). Secondary analyses will use log-
binomial regression models for binary outcomes and
linear regression models for continuous outcomes, with
generalised estimating equations used to account for
dependence due to multiple births. Missing data will be
multiply imputed under a missing at random assump-
tion. Sensitivity analyses will also be performed using
the original unimputed data.
In planned sub-group analyses of the primary and sec-
ondary outcomes we will examine the effect of DHA
supplementation on boys and girls separately, and on in-
fants with gestational age less than 27 completed weeks
or 27 to less than 29 completed weeks separately. Effect
modification by these two factors (sex and gestational
age) will be assessed separately by including interaction
effects in the statistical models. Separate estimates of
treatment effect will be obtained for males and females
and for infants born less than 27 completed weeks’ ges-
tation and 27 to less than 29 weeks’ gestation, independ-
ent of whether the interaction effect is statistically
significant, since this is a priori of interest.
Data monitoring and harms
An independent Trial Monitoring Committee has been
set up to review the progress of the trial and provide
feedback to the Trial Management Committee. The
Trial Monitoring Committee reviews general study pro-
gress (recruitment, compliance, loss to follow-up), the
BPD event rate and key secondary/safety outcomes.
The Trial Monitoring Committee provides advice re-
garding external issues that may impact on the N3RO
trial (for example changes in clinical practice). The
committee meets annually or as required and consists
of two neonatologists with clinical trials experience,
and a statistician with clinical trials expertise.
An independent (blinded) Serious Adverse Event
Committee has been established to review serious ad-
verse events. There are no serious adverse events which
would be anticipated as a unique consequence of partici-
pation in the trial, however all deaths are to be reported.
The Serious Adverse Event Committee includes experts
in neonatology and pathology who are not involved in
the trial. The primary role of the Serious Adverse Event
Committee is to review all deaths to determine whether
there is any likelihood that involvement in the trial could
have contributed to the death. The cause of the death is
determined from the autopsy results or other hospital
summary of the death by the relevant medical personnel.
This committee meets six monthly, or as required.
Any event that in the opinion of an Investigator may
be of immediate or potential concern for an infant’s
health or well-being is to be reported immediately to the
Chair of the Steering Committee. Expected events such
as necrotising enterocolitis, BPD, intracranial abnormal-
ity, pulmonary haemorrhage and patent ductus arterio-
sus are captured by data collection in the Case Report
Form. These data are available for review by the Trial
Monitoring Committee.
Research ethics approval
This protocol and the informed consent document have
been approved by the Human Research Ethics Commit-
tee (HREC) of each study site. Australia: Southern Adel-
aide Clinical HREC (Coordinating HREC and Flinders
Medical Centre, Adelaide); Women’s and Children’s
Health Network HREC (Women’s and Children’s Hos-
pital, Adelaide); The Royal Women’s Hospital HREC
(Royal Women’s Hospital, Melbourne); The Southern
Health HREC (Monash Medical Centre); Mercy Health
HREC (Mercy Hospital for Women, Melbourne); Women
and Newborn Health HREC (King Edward Memorial
Hospital, Perth); Hunter New England HREC (John
Hunter Hospital, Newcastle; Liverpool Hospital,
Sydney; Royal Hospital for Women, Sydney; Mater
Mothers’ Hospital, Brisbane). New Zealand: Northern
B Health and Disability HREC (Wellington Hospital,
Wellington; Waikato Hospital, Hamilton). Singapore:
SingHealth Centralised Institutional Review Board E
(KK Women’s and Children’s Hospital).
Any subsequent modifications will be reviewed and
approved by the HREC of each study site. The study will
be conducted in compliance with the current version of
the protocol. Any change to the protocol document or
informed consent form that affects the scientific intent,
study design, patient safety, or may affect a participant’s
willingness to continue participation in the study will be
considered a major amendment. All such amendments
will be submitted to the HREC for approval. Any other
changes to the protocol (such as administrative changes
to dates and study personnel) will be considered minor
amendments and will be notified to the HREC as
appropriate.
Confidentiality
Participant confidentiality is strictly held in trust by the
participating investigators and research staff and their
agents. This confidentiality is extended to cover testing
of biological samples in addition to the clinical informa-
tion relating to participants. The study protocol, docu-
mentation, data and all other information generated will
be held in strict confidence. No information concerning
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the study or the data will be released to any unauthor-
ised third party, without prior written approval of the
Coordinating Centre. The Coordinating Centre and
regulatory authorities may inspect all documents and
records required to be maintained by the Investigator,
including but not limited to, medical records and phar-
macy records for the infants in this study subject to in-
dividuals having obtained approval/clearance through
State/National Governments and HREC as required by
local laws. The study site will permit access to such re-
cords. Clinical information will not be released without
written permission of the parent/guardian, except as ne-
cessary for monitoring by HREC or regulatory agencies.
Discussion
This protocol describes a randomised controlled trial
comparing the effect of an enteral emulsion providing
supplementary DHA (60 mg/kg/day) with a control en-
teral emulsion containing no DHA on the incidence of
BPD in preterm infants born < 29 weeks’ gestation. BPD
is a serious complication of preterm birth, associated
with long-term morbidity. Both animal and human stud-
ies point to the possibility that DHA may have a primary
role in the prevention of BPD however there have been
no randomised controlled trials designed specifically to
determine the effect of DHA on BPD. To the best of our
knowledge this is the first such randomised controlled
trial. Results from this study will provide the first high
quality evidence on whether an enteral DHA supple-
ment reduces the incidence of BPD in very preterm
infants.
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